Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

You may not qualify if:

• Investigational agent within 4 weeks of first dose of study treatment
• Prior bevacizumab or tyrosine-kinase inhibitor
• History of allergic reactions or intolerance to any of the required agents on the study
• Any condition that would prohibit patient from initiating valproic acid. Current or prior valproic acid treatment is allowed (do not need to be ≥ LLN for laboratory for enrollment).
• Seizure disorder necessitating the use of enzyme-inducing antiepileptic drugs (EIAEDs). Efforts may be made by the treating physician to change the antiepileptic drug from another agent to valproic acid or non-EIAED prior to excluding the patient from study
• Contraindication to antiangiogenic agents, including:
• Bronchopulmonary hemorrhage/bleeding event \>= grade 2 (NCI Common Terminology Criteria for Adverse Events \[CTCAE\] version 4.0) within 4 weeks or less prior to first dose of study drug
• Any other hemorrhage/bleeding event \>= grade 3 (NCI CTCAE v4.0) within 4 weeks or less prior to first dose of study treatment
• Radiological evidence of any intracranial hemorrhage within the 4 weeks or less less prior to first dose of study treatment
• History of significant intratumoral, intracerebral, or subarachnoid hemorrhage
• Serious non-healing wound, ulcer, or bone fracture
• Documented bowel perforation within 6 months of the start of study treatment.
• Major surgery within 2 weeks of the start of study treatment, or ongoing complications from surgeries performed previously
• Clinically significant cardiac disease, including major cardiac dysfunction, such as uncontrolled angina, clinical congestive heart failure with New York Heart Association (NYHA) class III or higher, ventricular arrhythmias requiring antiarrhythmic therapy, recent (within 6 months) myocardial infarction or unstable coronary artery disease.
• Systolic blood pressure (BP) \> 160 mm Hg or diastolic pressure \> 100 mm Hg despite optimal medical management
• +16 more criteria